ConductScience.org, home

Paper4507516

Chemotherapy through lysosomes with a DNA-daunorubicin complex.

Trouet A and 2 others. Nat New Biol, 1972. Cited by 274 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Chemotherapy through lysosomes with a DNA-daunorubicin complex. Papers, record 4507516. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4507516

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chemotherapy through lysosomes with a DNA-daunorubicin complex.
PubMed
Journal
Nat New Biol
PubMed
Year
1972
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
274
iCite
Relative citation ratio, by iCite
8.76
iCite
Revised in PubMed
2019-09-08
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Trouet AA
2Deprez-de Campeneere DD
3De Duve CC

Source PubMed

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DNAMajor topic
DaunorubicinMajor topic
LysosomesMajor topic
Animals
Cells, Cultured
Drug Combinations
Injections, Intravenous
Leukemia, Experimental
Leukemia, Myeloid
Mice
Mice, Inbred DBA
Mice, Inbred Strains
Pinocytosis
Protein Binding
Sarcoma, Experimental
Staphylococcus

Source PubMed

Cited by60

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 274 citations.

PMIDTitleJournalYearIn PapersSource
38,531,786pH-Dependent Non-Covalent Release of Chemotherapy from Carriers.Discov Med2024https://conductscience.org/library/papers/38531786PubMed
36,365,245pH-Sensitive Targeting of Tumors with Chemotherapy-Laden Nanoparticles: Progress and Challenges.Pharmaceutics2022https://conductscience.org/library/papers/36365245PubMed
31,382,405Sustained Release of Minor-Groove-Binding Antibiotic Netropsin from Calcium-Coated Groove-Rich DNA Particles.Pharmaceutics2019https://conductscience.org/library/papers/31382405PubMed
31,058,802Nanomedicines for the Delivery of Biologics.Pharmaceutics2019https://conductscience.org/library/papers/31058802PubMed
30,954,222Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin.Biochem Biophys Res Commun2019https://conductscience.org/library/papers/30954222PubMed
30,613,436Advances in delivery systems for doxorubicin.J Nanomed Nanotechnol2018https://conductscience.org/library/papers/30613436PubMed
27,974,700Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).Oncotarget2017https://conductscience.org/library/papers/27974700PubMed
26,568,330Penetration and intracellular uptake of poly(glycerol-adipate) nanoparticles into three-dimensional brain tumour cell culture models.Exp Biol Med (Maywood)2016https://conductscience.org/library/papers/26568330PubMed
9,587,947Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy.Pharm Res1998https://conductscience.org/library/papers/9587947PubMed
8,792,417Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution.Pharm Res1996https://conductscience.org/library/papers/8792417PubMed
8,431,358Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro.Br J Cancer1993https://conductscience.org/library/papers/8431358PubMed
7,471,318Comparative toxicity of detorubicin and doxorubicin, free and DNA-bound, for hemopoietic stem cells.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/7471318PubMed
7,397,945Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/7397945PubMed
7,261,253Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7261253PubMed
7,108,944Phagosomal membrane lipids of LM fibroblasts.J Membr Biol1982https://conductscience.org/library/papers/7108944PubMed
7,023,715Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7023715PubMed
6,952,214
A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.
Proc Natl Acad Sci U S A1982https://conductscience.org/library/papers/6952214PubMed
6,524,928Drug targeting by drug entrapment into ultrafine compartments as carriers.Appl Biochem Biotechnol1984https://conductscience.org/library/papers/6524928PubMed
6,182,024Conjugates of adenine 9-alpha-D-arabinofuranoside monophosphate (ara-AMP) with lactosaminated homologous albumin are not immunogenic in the mouse.Experientia1982https://conductscience.org/library/papers/6182024PubMed
4,598,351Lysosomes in cancer cells.J Clin Pathol Suppl (R Coll Pathol)1974https://conductscience.org/library/papers/4598351PubMed

See all 60 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4507516

GET https://conductscience.org/api/papers/v1/4507516/cited_by?page=2